Business:
Small Molecules
Drug notes:
STX-721 Clin0 NSCLC; STX-241 Clin0 NSCLC; 3 add'l RD programs
About:
Scorpion Therapeutics is expanding the potential of precision medicine to cancer patients. Using their fully integrated discovery platform that uses cancer biology, medicinal chemistry, chemical proteomics and molecular biophysics, Scorpion is advancing drug discovery, small molecule design and target identification to rapidly create selective small molecule compounds against an unprecedented spectrum of targets. Scorpion is currently focusing on validated oncogene targets as well as undruggable targets and novel cancer targets. Their lead program, STX-478, is an oral inhibitor of PI3K-alpha that is in clinical stages as a monotherapy for patients with breast cancer.